|
|
View Clinical Trial (Medical Research Study)
|
A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy - NCT00887458-48201 (Clinical Trial 288683)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy288683.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Detroit |
|
State:
|
|
MI |
| Zip Code: |
|
48201 |
| Conditions: |
|
Prostate Cancer |
| Purpose: |
|
This research is being done to test an investigational drug, called itraconazole, in the
treatment of prostate cancer. Itraconazole is approved by the Food and Drug Administration
(FDA) for the treatment of various fungal infections such as fingernail/toenail infections
and other more serious fungal infections. The word "investigational" means that itraconazole
is not approved for use in people with cancer. However, the FDA is allowing the use of
itraconazole in this research study. Itraconazole has been shown to have activity against
cancer (including prostate cancer) in the laboratory, but has not been tested against cancer
in humans.
The purpose of this study is to find out:
- If itraconazole is safe when given at two different doses
- How itraconazole affects prostate specific antigen (PSA): a blood test that measures
substances released by prostate cancer
- Whether itraconazole can delay further prostate cancer growth and spread
- How itraconazole affects other markers of prostate cancer
|
| Study summary: |
|
Itraconazole is an oral, generic, and commercially available antifungal drug with a long
safety record when used at doses ranging from 200 to 600 mg daily.
Itraconazole has been shown in cellular and animal models to be a potent angiogenesis
inhibitor as well as a Hedgehog pathway antagonist; both pathways are considered important
in prostate cancer. Itraconazole has not previously been tested as an antineoplastic agent,
but given its well-established safety profile, the gap between further preclinical studies
and human clinical trials can be narrowed to accelerate development of this agent as a
putative anticancer drug. We hypothesize that itraconazole will prevent PSA progression in a
significant proportion of men with metastatic CRPC and that it will have an acceptable
safety profile at both doses. Itraconazole may ultimately delay the need for chemotherapy in
these men. |
| Criteria: |
|
Inclusion Criteria:
- Histologically or cytologically confirmed prostate adenocarcinoma.
- Presence of distant metastases on bone scan, CT scan, or MRI scan.
- Progression after androgen deprivation (and anti-androgen withdrawal).
- Rising serum PSA (Prostate Cancer Working Group (PCWG2) definition).
- Castrate levels of serum testosterone (i.e., ≤ 50 ng/dL).
- Age > 18 years.
- ECOG performance status score ≤ 2, and/or Karnofsky score ≥ 50%.
- Life expectancy > 6 months.
- Adequate kidney, liver, and bone marrow function.
- Willingness to sign informed consent and adhere to study requirements.
Exclusion Criteria:
- Recent surgery, radiation therapy, combined androgen blockade, or investigational
therapies in the last 8 weeks.
- Previous chemotherapy for metastatic prostate cancer.
- Concomitant use of second-line hormonal agents (e.g., ketoconazole, DES)
- Current use of corticosteroids, except if on a stable dose for ≥ 3 months.
- History of malabsorption syndrome (may affect itraconazole absorption).
- Allergic reactions to itraconazole or similar compounds.
- Concurrent use of drugs that interact with the CYP3A4 system (caution only).
- Presence of known brain metastases.
- Prior malignancy in the last 3 years, with some exceptions.
- Uncontrolled major infectious, cardiac, or pulmonary illnesses.
- Prolonged corrected QT interval (> 450 msec) on electrocardiography. |
|
|
|
| Study is available at: |
|
Karmanos Cancer Center
Detroit, MI 48201
United States
Primary Contact:
Brenda Dickow, RN
Email: dickowb@karmanos.org
Phone: 313-576-9372
Secondary Contact:
Serina King
Email: sking18@jhmi.edu
Phone: 410-614-6139 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 16, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|
|
|
|